Back to Search
Start Over
Efficacy of fesoterodine over 24 hours in subjects with overactive bladder
- Source :
- Current medical research and opinion, 26(4), 813-818. Taylor and Francis Ltd.
- Publication Year :
- 2010
- Publisher :
- Informa Healthcare, 2010.
-
Abstract
- Fesoterodine is an antimuscarinic agent indicated for the treatment of overactive bladder (OAB) symptoms. The objective of this study was to evaluate the efficacy of fesoterodine versus placebo over selected intervals during a 24-hour period in subjects with OAB. In a post hoc analysis, data were analyzed from two randomized, double-blind, placebo-controlled 12-week phase III trials in which subjects with a history of OAB symptoms for 6 months were treated with morning doses of fesoterodine 4 mg, fesoterodine 8 mg, or placebo. These trials are registered at ClinicalTrials.gov (NCT00220363 and NCT00138723). Changes were evaluated in number of micturitions, urgency episodes, urgency urinary incontinence (UUI) episodes, and mean voided volume (MVV) divided into three 8-hour intervals: 08:00-15:59 (daytime), 16:00-23:59 (evening), and 00:00-07:59 (nighttime). Comparisons with placebo were made using analysis of covariance (for least squares mean changes) and Wilcoxon rank sum test (for median percent changes); differences were considered significant at p
- Subjects :
- Adult
Male
medicine.medical_specialty
Evening
Urology
Urinary incontinence
Muscarinic Antagonists
Placebo
Drug Administration Schedule
Post-hoc analysis
Fesoterodine
medicine
Humans
Benzhydryl Compounds
Least-Squares Analysis
Trial registration
Aged
Randomized Controlled Trials as Topic
Morning
Aged, 80 and over
Dose-Response Relationship, Drug
Urinary Bladder, Overactive
business.industry
General Medicine
Middle Aged
medicine.disease
Overactive bladder
Female
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 14734877 and 03007995
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Current Medical Research and Opinion
- Accession number :
- edsair.doi.dedup.....2eefb39ee7750d7ffcd89e668251a485